Pharmacokinetics of indocyanine green in rats with experimentally induced hepatic diseases. 1993

T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
Faculty of Pharmaceutical Sciences, Okayama University, Japan.

The pharmacokinetics of indocyanine green (ICG) following intravenous administration was compared between normal rats and rats with experimentally induced acute hepatic diseases; namely D-galactosamine-intoxicated (GAL) rats, CDl4-intoxicated (CCl4) rats and rats with obstructive jaundice (OJ). The total body clearance of ICG was decreased in all rats with these hepatic diseases, especially in the rats with OJ. Hepatic plasma flow was also decreased in all rats with the three hepatic diseases. The profile of biliary excretion of ICG was characteristic of rats with each hepatic disease. The cumulative biliary excretion of ICG was markedly low in GAL rats, almost unchanged in CCl4 rats and the appearance of ICG was markedly delayed in rats with OJ. The pharmacokinetic analysis of these data showed that the decreased total plasma clearance of ICG in GAL and CCl4 rats results from both lowered influx across the sinusoidal plasma membrane of hepatocytes and the decreased hepatic plasma flow. In rats with OJ, the decreased total plasma clearance results only from a markedly lowered influx across the sinusoidal plasma membrane of hepatocytes without any relation to the decreased hepatic plasma flow. The decreased biliary recovery in GAL rats might relate to the decreased bile flow. The time lag of the appearance of ICG into the bile of rats with OJ was due to its slow efflux across the bile canalicular membrane, in addition to its slow influx across the sinusoidal membrane of the hepatocyte and its remarkably long period of stay in the hepatocyte.

UI MeSH Term Description Entries
D007208 Indocyanine Green A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output. Cardio-Green,Cardiogreen,Ujoveridin,Vofaverdin,Vophaverdin,Wofaverdin,Cardio Green,Green, Indocyanine
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008102 Liver Circulation The circulation of BLOOD through the LIVER. Hepatic Circulation,Circulation, Liver,Circulation, Hepatic
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002251 Carbon Tetrachloride A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed) Tetrachloromethane,Tetrachloride, Carbon
D002779 Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS). Bile Duct Obstruction,Biliary Stasis,Bile Duct Obstructions,Biliary Stases,Cholestases,Duct Obstruction, Bile,Duct Obstructions, Bile,Obstruction, Bile Duct,Obstructions, Bile Duct,Stases, Biliary,Stasis, Biliary
D005688 Galactosamine

Related Publications

T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
March 1994, Arzneimittel-Forschung,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
September 1983, The Journal of pharmacy and pharmacology,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
March 2021, Photodermatology, photoimmunology & photomedicine,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
May 1980, Biochemical pharmacology,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
September 1984, Canadian journal of physiology and pharmacology,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
December 1960, Gastroenterology,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
May 1982, The British journal of nutrition,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
March 1983, Biochemical pharmacology,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
December 1960, Proceedings of the staff meetings. Mayo Clinic,
T Kimura, and S Nakayama, and T Yamao, and Y Kurosaki, and T Nakayama
January 2014, BioMed research international,
Copied contents to your clipboard!